natgillin/translations-raw huggingface dataset:
There are no significant differences in the AUC of carbidopa or entacapone between younger (45–64 years) and older people (65–75 years).
Med mlajšimi (45-64 let) in starejšimi (65-75 let) osebami ni značilne razlike v AUC vrednostih karbidope ali entakapona.
There are no significant differences in the AUC of carbidopa or entacapone between younger (45–64 years) and older people subjects (65–75 years).
Med mlajšimi (45-64 let) in starejšimi (65-75 let) osebami ni značilne razlike v AUC vrednostih karbidope ali entakapona.
There are no significant differences in the AUC of carbidopa or entacapone between younger (45–64 years) and older people(65–75 years).
Med mlajšimi (45-64 let) in starejšimi (65-75 let) osebami ni značilne razlike v AUC vrednostih karbidope ali entakapona.
There are no significant gender-related differences in telbivudine pharmacokinetics.
Farmakokinetične lastnosti telbivudina se glede na spol bistveno ne razlikujejo.
There are no significant race-related differences in telbivudine pharmacokinetics.
Farmakokinetične lastnosti telbivudina se glede na raso bistveno ne razlikujejo.
There are no special instructions for use in elderly patients with normal organ function.
Ni posebnih navodil za uporabo pri starejših bolnikih z normalnim delovanjem organov.
There are no special instructions for use in elderly patients with regular organ function.
Ni posebnih navodil za uporabo pri starejših bolnikih z normalnim delovanjem organov.
There are no special precautions for the person who gives Ingelvac CircoFLEX or comes into contact with the animal.
Osebi, ki daje cepivo Ingelvac CircoFLEX ali pride v stik z živaljo, ni treba upoštevati posebnih previdnostnih ukrepov.
There are no special precautions needed for the treatment of patients aged from 65 years and over.
Za zdravljenje starejših bolnikov, starih 65 let in več, niso potrebni posebni previdnostni ukrepi.
There are no special storage instructions.
Za shranjevanje zdravila niso potrebna posebna navodila.
There are no specific studies about the ability to drive vehicles and use machinery.
Specifičnih študij o sposobnosti za vožnjo in upravljanje s stroji niso izvedli.
There are no studies in breast-feeding women.
Študij o uporabi repaglinida pri doječih materah ni.
There are no studies on the effects of TYSABRI on the ability to drive and use machines.
Študij vpliva na sposobnost vožnje in upravljanja s stroji za zdravilo TYSABRI niso izvedli.
There are no studies using defibrotide in pregnant women.
Študij z defibrotidom pri nosečnicah ni.
There are no systematically collected data to specifically address switching patients from INVEGA to other antipsychotic medicinal products.
Ni sistematično zbranih podatkov, ki bi posebej obravnavali prehod bolnika z zdravila INVEGA na druga antipsihotična zdravila.
There are no systematically collected data to specifically address switching patients from ZYPADHERA to other antipsychotic medicinal products.
Sistemsko zbranih podatkov glede prehoda bolnikov z zdravilom ZYPADHERA na druga antipsihotična zdravila ni.
There are no virologic treatment stopping rules that apply to the combination of OLYSIO with sofosbuvir.
Smernic za ukinitev zdravljenja z zdravilom OLYSIO v kombinaciji s sofosbuvirjem ni.
There are only very few data available on patients with African origin.
Na voljo je zelo malo podatkov o bolnikih afriškega izvora.
There are post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g, intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics.
V obdobju trženja so ob sočasni uporabi pregabalina z zdravili, ki povzročajo zaprtost, kot npr. opioidni analgetiki, poročali o učinkih, povezanih z zmanjšanjem delovanja spodnjega gastrointestinalnega trakta (npr. črevesna zapora, paralitični ileus, zaprtje).
There are post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g. intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics.
V obdobju trženja so ob sočasni uporabi pregabalina z zdravili, ki povzročajo zaprtost, kot npr. opioidni analgetiki, poročali o učinkih, povezanih z zmanjšanjem delovanja spodnjega gastrointestinalnega trakta (npr. črevesna zapora, paralitični ileus, zaprtje).
There are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g. intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics.
V obdobju trženja so ob sočasni uporabi pregabalina z zdravili, ki povzročajo zaprtost, kot npr. opioidni analgetiki, poročali o učinkih, povezanih z zmanjšanjem delovanja spodnjega gastrointestinalnega trakta (npr. črevesna zapora, paralitični ileus, zaprtje).
There are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics.
V obdobju trženja so ob sočasni uporabi pregabalina z zdravili, ki povzročajo zaprtost, kot npr. opioidni analgetiki, poročali o učinkih, povezanih z zmanjšanjem delovanja spodnjega gastrointestinalnega trakta (npr. črevesna zapora, paralitični ileus, zaprtje).
There are rare reports of organisms with metallo-beta-lactamases (MBLs), Class B, that are resistant to aztreonam, VIM-5
Ni poročil o organizmih z metalo-betalaktamazami (MBL), razred B, ki so odporne na aztreonam, VIM-5 (K. pneumoniae in
There are reports of patients who have taken the recommended dose for more than 5 days of treatment (up to 64 days) with adverse reaction reported including bone marrow suppression, with or without infection, in some cases severe and prolonged and resulting in death.
Obstajajo poročila o bolnikih, ki so jemali priporočen odmerek več kot 5 dni zdravljenja (do 64 dni), neželeni učinki pa so vključevali supresijo kostnega mozga z okužbo ali brez nje, ki je bila v nekaterih primerih huda in dolgotrajna ter je povzročila smrt.
There are reports of patients who have taken the recommended dose for more than 5 days of treatment (up to 64 days) with adverse reactions reported including bone marrow suppression, with or without infection, in some cases severe and prolonged and resulting in death.
Obstajajo poročila o bolnikih, ki so jemali priporočen odmerek več kot 5 dni zdravljenja (do 64 dni), neželeni učinki pa so vključevali supresijo kostnega mozga z okužbo ali brez nje, ki je bila v nekaterih primerih huda in dolgotrajna ter je povzročila smrt.
There are several varieties (called genotypes) of hepatitis C virus and Harvoni is recommended for use in patients with virus of genotypes 1, 4, 5 and 6 and for some patients with genotype 3.
Poznamo več različic (imenovanih genotipi) virusa hepatitisa C. Zdravilo Harvoni je priporočeno za uporabo pri bolnikih z virusom genotipa 1, 4, 5 in 6 ter pri nekaterih bolnikih z genotipom 3.
There are some case reports of reduced efficacy of antidepressants, antipsychotics (including lithium) and benzodiazepines coincidental to the initiation of orlistat treatment in previously well controlled patients.
Poročali so o primerih zmanjšane učinkovitosti antidepresivov, antipsihotikov (vključno z litijem) in benzodiazepinov, ki se je pojavila hkrati z začetkom zdravljenja z orlistatom, pri predhodno dobro kontroliranih bolnikih.
There are some case reports of reduced efficacy of antiretroviral HIV medicines, antidepressants antipsychotics (including lithium) and benzodiazepines coincidental to the initiation of orlistat treatment in previously well-controlled patients.
Obstaja nekaj poročil o zmanjšanju učinkovitosti protiretrovirusnih učinkovin za zdravljenje okužbe s HIV, antidepresivov, antipsihotikov (vključno z litijem) in benzodiazepinov, ki je sovpadalo s pričetkom zdravljenja z orlistatom pri predhodno urejenih bolnikih.
There are some medications that must not be taken with Ketoconazole HRA (see section 2).
Nekaterih zdravil ne smete jemati skupaj z zdravilom Ketokonazol HRA (glejte poglavje 2).
There are some medicines such as ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis), verapamil (a medicine used to lower blood pressure, to correct heart rhythm or to treat angina pectoris), antifungal medicines (e.g. ketoconazole and itraconazole) and some antiviral medicines (e.g. ritonavir) that must not be taken with Emselex.
če imate hude težave z jetri, nekaterih zdravil, na primer ciklosporina (zdravila, ki ga uporabljamo po presaditvi za preprečevanje zavrnitve presadka in pri drugih boleznih, na primer pri revmatoidnem artritisu ali atopijskem dermatitisu), verapamila (zdravila, ki ga uporabljamo za zniževanje krvnega tlaka, za zdravljenje motenj srčnega ritma ali za zdravljenje angine pektoris), protiglivičnih zdravil (npr. ketokonazola in itrakonazola) in nekaterih protivirusnih zdravil (npr. ritonavirja) ne smete jemati z zdravilom Emselex.
There are some medicines that should never be taken with Stribild:
Nekaterih zdravil ne smete nikoli uporabljati skupaj z zdravilom Stribild:
There are some medicines that should not be taken with EMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also Do not take EMEND).
Nekaterih zdravil med zdravljenjem z zdravilom EMEND ne smete jemati (kot so pimozid, terfenadin, astemizol in cisaprid), pri nekaterih pa je treba prilagoditi odmerek (glejte tudi "Ne jemljite zdravila EMEND").
There are some medicines that should not be taken with EMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also ‘Do not take EMEND’).
Nekaterih zdravil med zdravljenjem z zdravilom EMEND ne smete jemati (zdravil kot so pimozid, terfenadin, astemizol in cisaprid), pri nekaterih pa je treba prilagoditi odmerek (glejte tudi "Ne jemljite zdravila EMEND").
There are some medicines that should not be taken with IVEMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also ‘Do not use IVEMEND’).
Nekaterih zdravil se skupaj z zdravilom IVEMEND ne sme uporabljati (kot so pimozid, terfenadin, astemizol in cisaprid) ali pa je treba njihov odmerek prilagoditi (glejte tudi "Zdravila IVEMEND ne smete prejeti").
There are some medicines that you must not take with Agenerase (please see ‘Do not take Agenerase’ for further information).
Nekaterih zdravil ne smete jemati skupaj z zdravilom Agenerase (za dodatne informacije glejte 'Ne jemljite zdravila Agenerase').
There are some medicines that you should not give to your animal during treatment because if given together they might cause serious adverse effects.
V času zdravljenja živali ne smete dajati nekaterih zdravil, ker sočasno dajanje lahko povzroči resnejše stranske učinke.
There are some medicines you cannot take at all with Norvir.
Med jemanjem zdravila Norvir sploh ne smete uporabljati nekaterih zdravil.
There are some medicines you must not take with Exviera - see the previous table “Medicines you must not take with Exviera”.
Obstajajo nekatera zdravila, ki jih ne smete jemati z zdravilom Exviera – glejte prejšnjo preglednico “Zdravila, ki jih ne smete jemati z zdravilom Exviera”.
There are some medicines you must not take with Viekirax see the previous table “Medicines you must not take with Viekirax”.
Obstajajo nekatera zdravila, ki jih ne smete jemati z zdravilom Viekirax – glejte prejšnjo preglednico “Zdravila, ki jih ne smete jemati z zdravilom Viekirax”.
There are still some small air bubbles remaining.
V vložku je še nekaj majhnih mehurčkov zraka.
There are still some small air bubbles remaining.
V vložku še nekaj majhnih mehurčkov zraka.
There are strict laws on the use, handling and disposal of medicines like Xofigo.
Uporabo zdravilu Xofigo podobnih zdravil, ravnanje z njimi in njegovo odstranjevanje določajo strogi zakoni.
There are three conclusive cases with positive dechallenge and a potential mechanism exists through which lomitapide might cause alopecia i.e. malabsorption of fat soluble vitamins.
Obstajajo trije prepričljivi primeri okrevanja po prekinitvi jemanja zdravila in obstaja potencialen mehanizem, preko katerega bi lahko lomitapid povzročil alopecijo, tj. malabsorpcija v maščobi topnih vitaminov.
There are three groups:
Obstajajo tri skupine:
There are toxicities that require interruption of Viramune therapy (see section 4.4).
Pojavijo se lahko toksični učinki, zaradi katerih je potrebno prekiniti zdravljenje z zdravilom Viramune, (glejte poglavje 4.4).
There are toxicities that require interruption of Viramune therapy (see section 4.4).
Pojavijo se lahko toksični učinki, zaradi katerih je treba zdravlejnje z zdravilom Viramune prekiniti, (glejte poglavje 4.4).
There are two alternative treatment schedules:
Na voljo sta dva možna režima zdravljenja:
There are two caps – one is grey and labelled ‘1’ and the other is plum and labelled ‘2’.
Nameščena ima dva pokrovčka – eden je siv in označen z '1', drugi pa temnomoder in označen z '2'.
There are two different ways (routes) to inject MIRCERA into your body.
Zdravilo MIRCERA lahko injiciramo po dveh razli nih poteh.
There are two dosing regimes for adults:
Za odrasle obstajata dva režima odmerjanja:
There are two excipients: one is fibrin - a clear supportive layer used to keep Holoclar intact, the other one is a liquid containing amino acids, vitamins, salts and carbohydrates to store the cells in the vial called Dulbecco’s Modified Eagles Medium supplemented with L-glutamine.
Pomožni snovi sta dve: ena je fibrin – prosojna podporna plast, ki zagotavlja nepoškodovanost zdravila Holoclar, druga pa je tekoča in vsebuje aminokisline, vitamine, soli in ogljikove hidrate, s pomočjo katerih se celice shranijo v viali in se imenuje D-MEM (Dulbecco’s Modified Eagles Medium), gojišče za celice, obogateno z L-glutaminom.
There are two well- documented cases of delirium, both with positive rechallenge.
Obstajata dva dobro zabeležena primera delirija, pri katerih so se znaki in simptomi ponovili ob ponovni uvedbi zdravila.
There are very limited clinical data available in patients with performance status 2 to 4.
Kliničnih podatkov o bolnicah s stanjem zmogljivosti od 2 do 4 je zelo malo.
There are very limited data from the use of fingolimod in pregnant women.
Podatki o uporabi fingolimoda pri nosečnicah so zelo omejeni.
There are very limited safety and immunogenicity data available on the administration of an AS03- adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) and on administration of half a dose of the vaccine (i.e.
Pri otrocih, starih od 3 do 9 let, je zelo malo podatkov o varnosti in imunogenosti cepiva z adjuvansom AS03, z vsebnostjo 3,75 µg HA, pridobljenega iz A/Vietnam/1194/2004 (H5N1) in polovičnega odmerka istega cepiva (tj.
There are very limited safety and immunogenicity data available on the administration of an AS03- adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) manufactured using a different process and on administration of half a dose of the same vaccine (i.e.
Pri otrocih, starih od 3 do 9 let, je zelo malo podatkov o varnosti in imunogenosti cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Vietnam/1194/2004 (H5N1), izdelanega z uporabo drugačnega postopka, in polovičnega odmerka istega cepiva (tj.
There can also be a slight rise in body temperature, usually of no more than 1 °C, in the 24 hours following vaccination.
V 24 urah po cepljenju se lahko pojavi tudi rahlo povišanje telesne temperature, navadno za največ 1°C.
There continued to be evidence of increased response to treatment for up 2.5 years in all groups exposed to Revestive in terms of parenteral nutrition volume reduction, gaining additional days off parenteral nutrition per week, and achieving weaning of parenteral support.
V vseh skupinah bolnikov, ki so prejemali zdravilo Revestive, se je do 2,5 let dolgo kazal večji odziv na zdravljenje v smislu znižanja volumna parenteralne prehrane, povečanja števila dni na teden brez parenteralne prehrane in prenehanja parenteralne prehrane.
There could be damage to your nerves which may result in muscle pain, weakness and numbness.
Možne so poškodbe živcev, ki povzročijo mišično bolečino, oslabelost in otrplost.
There could be effects on your ability to drive and to use machines due to the medicine used in combination with Cuprymina.
Zdravila, uporabljena v kombinaciji z radiofarmacevtskim predhodnikom Cuprymina, lahko vplivajo na vašo sposobnost upravljanja vozil in strojev.
There could be effects on your ability to drive and to use machines due to the medicine used in combination with EndolucinBeta.
Zdravila, uporabljena skupaj z radionuklidnim predhodnikom EndolucinBeta, lahko vplivajo na vašo sposobnost upravljanja vozil in strojev.
There could be some reasons why Thymanax may not be suitable for you:
V nekaterih primerih zdravilo Thymanax ni primerno za vas:
There could be some reasons why Valdoxan may not be suitable for you:
V nekaterih primerih zdravilo Valdoxan ni primerno za vas:
There did not appear to be a relationship between baseline white blood cell (WBC) counts and development of hyperleukocytosis nor did there appear to be a correlation between baseline WBC count and peak WBC counts.
Ni ugotovljene povezave med osnovno vrednostjo števila belih krvnih celic (WBC – »white blood cell) in razvojem hiperlevkocitoze ali med osnovno in najvišjo vrednostjo WBC.
There does not appear to be an increased risk of malignancy with teriflunomide in the clinical trial experience.
Na osnovi izkušenj v kliničnih preskušanjih ne izgleda, da teriflunomid poveča tveganja za maligne bolezni.
There has also been 1 post-marketing report of a primary lung malignancy in an Exubera-treated patient.
V obdobju trženja je bil opisan 1 primer primarnega malignoma pljuč pri bolniku, zdravljenim z zdravilom EXUBERA.
There has been no dedicated study to assess the potential for lapatinib to prolong the QT interval.
Izvedena ni bila nobena namenska študija za oceno potenciala lapatiniba za podaljšanje intervala QT.
There has been no experience with overdose of Panretin.
Ni poročil o primerih prevelikega odmerjanja zdravila Panretin gel.
There have also been post-marketing reports of death by suicide, delusions and psychosis-like behaviour.
V obdobju trženja zdravila so poročali tudi o smrti zaradi samomora, blodnjavih motnjah in vedenju podobnem psihozi.
There have also been post-marketing reports of rare but severe cutaneous reactions, including Stevens-Johnson Syndrome and Erythema Multiforme in patients using varenicline.
V obdobju trženja so pri bolnikih, ki uporabljajo vareniklin, poročali tudi o redkih, vendar hudih kožnih reakcijah, vključno s Stevens-Johnsonovim sindromom in multiformnim eritemom.
There have also been post-marketing reports of severe depression, death by suicide, delusions and psychosis-like behaviour.
Tudi v obdobju trženja zdravila so poročali o hudi obliki depresije, smrti zaradi samomora, prividih in vedenju, podobnem psihozi.
There have also been post-marketing reports of severe depression, death by suicide, delusions and psychosis-like behaviour.
V postmarketinškem obdobju so poročali tudi o hudi depresiji, smrti zaradi samomora, blodnjah in vedenju, podobnem psihozam.
There have also been rare post-marketing reports of new onset heart failure, including heart failure in patients without known pre-existing cardiovascular disease.
Obstaja tudi nekaj redkih poročil iz obdobja trženja o novonastalem srčnem popuščanju, vključno s srčnim popuščanjem pri bolnikih brez znane predhodne srčnožilne bolezni.
There have also been reports of fluid accumulation, including peripheral oedema, lymphoedema, pleural effusion and pericardial effusions (including haemodynamically significant effusions in children and adults), in patients receiving Rapamune.
Pri bolnikih, ki so prejemali zdravilo Rapamune, so poročali tudi o kopičenju tekočine, vključno s perifernimi edemi, limfedemom, plevralnim izlivom in perikardialnimi izlivi (vključno s hemodinamsko pomembnimi izlivi pri otrocih in odraslih).
There have also been reports of patients developing a hole in the septum of the nose – the structure, which separates the nostrils.
Poročali so tudi o predrtju nosnega pretina – pregrade, ki ločuje nosnici.
There have also been reports of reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré Syndrome.
Poročali so tudi o učinkih, povezanih z demielinizacijo in ascendentno periferno nevropatijo, ki je bila podobna Guillain-Barréjevemu sindromu.
There have also been reports of severe skin reactions including Erythema Multiforme (a type of rash) and Stevens-Johnson Syndrome (a serious illness with blistering of the skin, mouth, around the eyes or genitals) and serious allergic reactions including angioedema (swelling of the face, mouth, or throat).
Poročali so tudi o primerih hudih kožnih reakcij, vključno z multiformnim eritemom (vrsta izpuščaja) in Stevens-Johnsonovim sindromom (resna bolezen z mehurji na koži, v ustih, okrog oči ali spolovil), ter resnih alergijskih reakcij, vključno z angioedemom (otekanje obraza, ust ali grla).
There have been a few cases of overdose due to accidental mistakes reported with Oncaspar.
Poročali so o nekaj primerih prevelikega odmerjanja zdravila Oncaspar zaradi nenamernih napak.
There have been cases of cancers other than lymphoma in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.
Pri bolnikih s posebno boleznijo pljuč, t.i. kronično obstruktivno pljučno boleznijo (KOPB), zdravljenih z nekim drugim zaviralcem TNF, so bili primeri rakov, ki niso bili limfomi.
There have been cases of cancers, including unusual types, in children and teenage patients taking TNF-blocking agents, which sometimes resulted in death (see further down “Children and adolescents”).
Pri otrocih in mladostnikih, ki so jemali zaviralce TNF, so se pojavili primeri raka, vključno z neobičajnimi oblikami, ki so se včasih končali s smrtjo (glejte še spodaj »Otroci in mladostniki«).
There have been cases of cancers, including unusual types, in children and teenage patients taking TNF-blocking agents, which sometimes resulted in death.
Pri nekaterih pediatričnih bolnikih in bolnikih mladostnikih, ki so prejemali "blokatorje" TNF se je razvil rak, vključno z zelo neobičajnimi oblikami, kar se je včasih končalo s smrtnim izidom.
There have been cases of cancers, other than lymphoma in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.
Pri bolnikih s posebno boleznijo pljuč, t.i. kronično obstruktivno pljučno boleznijo (KOPB), zdravljenih z nekim drugim zaviralcem TNF, so bili primeri rakov, ki niso bili limfomi.
There have been cases of cancers, other than lymphoma, have been reported in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.
Pri bolnikih s posebno boleznijo pljuč, t.i. kronično obstruktivno pljučno boleznijo (KOPB), zdravljenih z nekim drugim zaviralcem TNF, so bili primeri rakov, ki niso bili limfomi.
There have been cases of lymphoma of different varieties, in both clinical studies and the post- marketing setting, including a fatal case of Epstein-Barr virus (EBV) positive B-cell lymphoma.
V obeh kliničnih študijah in v okviru uporabe zdravila po njegovem prihodu na trg je prišlo do primerov limfoma različnih vrst, med katerimi je bil tudi smrten primer virus Epstein-Barr (EBV) pozitivnega B-celičnega limfoma.